Trial Profile
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2014
Price :
$35
*
At a glance
- Drugs HIV vaccine TBC-3B (Primary) ; HIV vaccine TBC-3B (Primary) ; HIV vaccine TBC-3B (Primary) ; Immunostimulants
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 11 Jun 2014 New trial record